RCT | Allo-HCT vs. standard consolidation chemotherapy in patients with intermediate-risk AML

Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Commentary: Allo-HCT Not Linked With Better OS vs Consolidation Chemotherapy in AML Patients in Complete Remission – AJMC

Commentary on Twitter

Rand trial suggests pts with intermediate-risk AML & matched donor have a significantly improved disease free-survival with allo-HCT during first complete remission (69% vs. 40%) but similar overall surv w/consol chemo & allo HCT only after relapse. https://t.co/TJR9fqcYc9

— JAMA Oncology (@JAMAOnc) February 9, 2023